The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Open accessAbstract
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The authors flow-sorted the edited cells on the basis of the BCL11A-dependent switch to fetal haemoglobin, sequenced guides enriched in cells that had or hadn’t switched, and on the basis of those enrichments, successfully identified a primate-specific GATA1 motif critical for that enhancer’s function.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Cas9 introduces a targeted double-strand break, which is repaired by homology-directed repair using the donor templates, resulting in the incorporation of a single variant at the endogenous genomic locus (54, 55).”
From Massively parallel functional genomic assays in endocrinology: from promise to delivery (2026) · cites this paper as [54]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first such screen targeted gRNAs to effectively tile small indels across a known cluster of enhancers of BCL11A195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Canver et al 9 recently showed BCL11A enhancer disruption by CRISPR/Cas9 could induce fetal haemoglobin in both mice and primary human erythroblast cells.”
From What is CRISPR/Cas9? (2016) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The initial CRISPR screens of regulatory elements delivered an individual gRNA per cell195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
The cited source says what the claim attributes to it.
In the citing paper
“To date, all such screens use Cas9-induced perturbations, including active Cas9 for sequence disruption195, or nuclease dead-Cas9 (dCas9) tethered to an epigenetic repressor105 or activator domain92.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
In the citing paper
“In contrast, nine recently published CRISPR screens of noncoding sequences cumulatively studied regulatory effects on a total of 17 genes (Canver et al., 2015; Diao et al., 2016, 2017; Fulco et al., 2016; Gasperini et al., 2017; Klann et al., 2017; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
In the citing paper
“First, they focus on the regulation of a single gene per experiment, typically entailing the development of a gene-specific assay.”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Cited by
Sorted by citations
Items 801–883 of 883
Subramanian, S., Thoms, J., Huang, Y., Cornejo, P., Koch, F. C., Jacquelin, S., Shen, S., Song, E., Joshi, S. M., Brownlee, C., et al. (2023) · bioRxiv · doi:10.1101/2023.04.18.537282
Base editors dissect genetic variants in human hematopoietic cells on a large scale
Papapetrou, E. P. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.05.009
Advances in the application of CRISPR/Cas9 system in the study of hematologic diseases and cancer
Yang, D. (2023) · International Conference on Biomedical and Intelligent Systems (IC-BIS) · doi:10.1117/12.2688210
Rivest, J.-F., Carter, S., Goupil, C., Cyr, D., Ung, R., Soglio, D. B. D., Mac‐Way, F., Waters, P. J., Paganelli, M., & Doyon, Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.29.559947
Progress and development of CRISPR-Cas tool in the treatment of thalassemia
Lu, F. J., Xu, Z., & Feng, W. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/8/20240425
Mumtaz, K., Hussain, I., Iftikhar, F., Rehman, F. U., Jameel, M., Farooq, S., Hassan, H., Fatima, A., Ottmann, O. G., & Mian, A. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.28.568974
Golov, A. K., Gavrilov, A. A., Kaplan, N., et al. (2023) · eLife · doi:10.7554/elife.91596.1.sa1
Prasad, M., Choudhuri, A., Yang, S. P., Flynn, E., Zon, L. I., & Zhou, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13222-3.00005-8
Applied Stem Cell Research in Sickle Cell Disease
Kiumarsi, A., Rostami, T., & Mohammadi, M. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00027-5
Gene Editing Approaches for Haematological Disorders
Ferrari, S., & Canarutto, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00053-6
Emerging trends in Sickle cell disease and CRISPR/Caspases
Ababio, G. K. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004305 · Cited by 1
Shen, N., Wang, R., Tang, Y., Hou, G., Shen, Y., Xiang, C., & Zhang, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93232-5.00016-2
Becerra, B., Wittibschlager, S., Patel, Z. M., Kutschat, A. P., Delano, J., Che, E., Karjalainen, A., Wu, T., Starrs, M., Jankowiak, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.09.612085
Self-citationUse of CRISPR system in genetic screening to detect neurodegenerative disease
Kar, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23826-0.00009-x
Wang, L., He, H., Li, Y., Wang, X., Yu, J., Huang, Y., Yu, K., He, J., Zhao, M., Xie, T., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155717
Golov, A. K., Gavrilov, A. A., Kaplan, N., & Razin, S. V. (2024) · eLife · doi:10.7554/elife.91596.2
Paired CRISPR screens to map gene regulation in cis and transPreprint
Xue, X., Gajic, Z. Z., Caragine, C. M., Legut, M., Walker, C. R., Kim, J. Y. S., Wang, X., Yan, R., Wessels, H., Lu, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.27.625752
Self-citationGenetic variants within silencer elements shape human blood cell phenotype diversityPreprint
Tan, M., van Weerd, J., Yavas, A., & Pang, B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632723
CRISPR/Cas9 gene editing for treating gene and protein disorders
Umeyor, C. E., Negi, P., Agarwal, R., Hanjankar, S. N., & Patravale, V. B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27416-9.00004-6
Functional interrogation of candidate cis -regulatory elements at the LDLR locusPreprint
Leix, K., Serrano-Zayas, C., Graham, S. E., & Emmer, B. T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.20.644385
MLL1 complex is a critical regulator of fetal hemoglobin repressionPreprint
Han, Y., Gudmundsdottir, B., Gudmundsson, K. O., Roy, K. R., Tisdale, J. F., & Du, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.24.645036
Functional enhancers: concept, screening, and validation
Lin, H., Chen, F., & Huang, J. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0113
Exploration of the mechanism of a novel enhancer on buffalo muscle development
Duan, S., Liu, X., Liu, W., Dou, Y., Xu, G., Zhang, F., Geng, K., Xiong, Q., & Chen, M. (2025) · Genomics · doi:10.1016/j.ygeno.2025.111071 · Cited by 1
Self-citationEnhancer Poising Enables Pathogenic Gene Activation by Noncoding VariantsPreprint
Hollingsworth, E. W., Chen, Z., Chen, C. X., Jacinto, S. H., Liu, T. A., & Kvon, E. Z. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.20.660819 · Cited by 1
Gene Therapy & Gene-Editing Techniques
LaRocca, C. J., & Steer, C. J. (2025) · Success in academic surgery · doi:10.1007/978-3-031-83034-1_13
Villarroel, J. J. G. (2025) · Orbis Tertius - UPAL · doi:10.59748/ot.v9i17.174
HLA-B27 as a potential target for the cure of axial spondyloarthritis
Cannistrà, C., Timilsina, S., Gershwin, M. E., & Selmi, C. F. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102611
Advancement of CRISPR/Cas9 in Translational Biomedicines
Atale, N., Kong, Q., & Rani, V. (2025) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-031-80973-6_5
CRISPR therapy for sickle cell disease
Charles, K. S., Maharaj, C. N., Mohammed, F. S., & Friday, M. (2025) · BMJ · doi:10.1136/bmj.r1596
Yang, J., Han, H., Wang, X., & Suh, Y. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.29.679215
PETRA: Prime editing of transcribed regulatory elements to assay expressionPreprint
Armas, M., Herger, M., Cubitt, L., & Findlay, G. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.18.689114
Kumari, P., Gupta, V., Chhikara, A., & Dalal, J. (2025) · Journal of Forensic and Legal Medicine · doi:10.1016/j.jflm.2025.103047 · Cited by 1
CRISPR/Cas9: the future of human gene editing
Zulkifli, N. D., Sani, S. B. M., Wong, C. H., Mahadzan, M., Suhimi, M. H. A., Zulkifli, N., & Das, K. T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33947-9.00009-8
Characterization of a cis-regulatory element upstream of matrix metalloproteinase-9
Rangaraj, A., Kaur, H., Mejia, L., Hansen, J., Biswas, A., & Tuteja, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-31297-3
Ain, Q. U., McCarthy, A., Nadeem, A., Javed, M., Niakan, K. K., & Fouladi-Nashta, A. A. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01774-z · Cited by 1
Sethi, S., Vorontsov, I. E., Kulakovskiy, I. V., Greenaway, S., Williams, J., Vsevolod, M., Brown, S. D. M., Simon, M. M., & Mallon, A.-M. (2020) · Figshare · doi:10.6084/m9.figshare.13181407
Additional file 1 of MAUDE: inferring expression changes in sorting-based CRISPR screens
de Boer, C. G., Ray, J., Hacohen, N., & Regev, A. (2020) · Figshare · doi:10.6084/m9.figshare.12421364
Xue, M., Dong, L., Zhang, H., Li, Y., Qiu, K., Zhao, Z., Gao, M., Han, L., Chan, A., Li, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25132035
Enfoque terapéutico de la anemia falciforme
Soto-Manzano, A. V., Córdoba-García, S., Castaño, L. M. F., Uribe-Ramírez, M., & Sánchez, L. M. M. (2025) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1553
Disrupting epigenetic insulation underlies CRISPR therapy for β-hemoglobinopathies
Wang, K., Wang, J., Weiss, M. J., Yue, F., & Xu, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.015
CRISPR-HAWK: Haplotype- and Variant-Aware Guide Design Toolkit for CRISPR-CasPreprint
Kumbara, A., Tognon, M., Carone, G., Fontanesi, A., Bombieri, N., Giugno, R., & Pinello, L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.27.696698
Self-citationIn utero gene therapy: Pioneering diagnostic and therapeutic technologies
Seth, S., Sen, M., Banerjee, S., Sau, R., & Ray, S. (2025) · Human Gene · doi:10.1016/j.humgen.2025.201527
Spatial control of genome editing activity enables localized immunotherapyPreprint
Yang, X., Tong, L., Pan, Y., Huang, J., Yi, Z., He, D., Liu, J., Wang, C., Liang, Y., & Tong, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.699490
Precision CRISPR annotation of the functional enhancer landscape in primary human T cellsPreprint
Wang, P., Giles, J. R., Huang, H., Manne, S., Jordan, M. S., Huang, A. C. C., Shi, J., & Wherry, E. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.27.702006
CRISPR mutagenesis of the MYC locus reveals a druggable ultraconserved RNA element
Shi, P., Yang, F., Tala, F. N. U., Huang, W., Xing, L., Alam, S., Dai, W., Aparicio, A. O., Kalicki, C. H., Trehan, A., et al. (2026) · Cell · doi:10.64898/2026.01.29.702547
Near completely reversing the γ- to β-globin switch by enhancer release, retargeting and reinforcingPreprint
Wang, N., Yang, K., Xie, X., Cui, S., Pei, X., Zhao, X., Hao, D., Jia, Y., Yang, G., Liu, R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702713
LDB1 represses fetal hemoglobin expression by enhancing BCL11A transcription
Park, S.-W., Choi, C., Park, I.-B., Kang, S. J., Lee, H. J., Kim, J.-I., Bae, J., Geum, D., Cheon, Y. P., & Chun, T. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104070
Luo, S., Lin, L., Zhang, H., Yang, Y., Liu, Y., Han, Y., Chen, F., Liang, R., Niang, X., Dai, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.02.703403
Functional interrogation of candidate cis-regulatory elements at the LDLR locus
Leix, K., Serrano-Zayas, C., Vyas, H., Graham, S. E., & Emmer, B. T. (2026) · PLoS Genetics · doi:10.1371/journal.pgen.1012082 · Cited by 1
Genetic influences on haematopoiesis
Poeschla, M., & Sankaran, V. G. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-00947-1 · Cited by 1
Mannstadt, M., & Wein, M. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00041-4
New therapeutic strategies for the treatment of β-hemoglobinopathies
Weber, L. (2018) · theses.fr (ABES) · doi:10.70675/09314463zdfd1z46b4z9c0cz32c6c2c5ccc2
High-throughput study of silencer elements in T cells
Hussain, S. (2019) · theses.fr (ABES) · doi:10.70675/76751597z8779z4919z9882z87ac3dea2dc4
Génotoxicité des systèmes CRISPR-Cas9.
Cullot, G. (2019) · theses.fr (ABES) · doi:10.70675/cb1809e4zaafbz4fc1z89e9zeb0e5fd69275
Caractérisation des enhancers dérégulés dans la leucémie aiguë lymphoblastique de type T
España, A. P. (2019) · theses.fr (ABES) · doi:10.70675/5c13bdf2zac72z45c4z91e7z396bdaa5ddc4
Gene coregulation in cis within the 3D genome – A single-molecule imaging study
Kerlin, M. A. (2021) · theses.fr (ABES) · doi:10.70675/95774cf6z713dz4df5z92b1z76204ad8b669
Base editing approaches for the treatment of β-hemoglobinopathies
Antoniou, P. (2021) · theses.fr (ABES) · doi:10.70675/c4dddb32zf8aez4bc3z8cf8zce9a4e808265
Base editing approaches for the treatment of ß-hemoglobinopathies
Hardouin, G. (2022) · theses.fr (ABES) · doi:10.70675/593cd291z9d0ez45a6z82cdz64ffb2e65ff8
Genome and epigenome editing approaches to treat β-hemoglobinopathies
Fontana, L. (2024) · theses.fr (ABES) · doi:10.70675/f1623d8bz5529z4d2dzb255z45ed273f643c
Cohrt, K. O., & O’Dea, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083384
Singh, A., Kumar, R., Chauhan, P., Mallikarjuna, M., Thaker, R., & Sambhav, K. (2026) · Cureus · doi:10.7759/cureus.108691
The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care
Tardif, M., Saby, M., Forté, S., & Pincez, T. (2026) · Cells · doi:10.3390/cells15100939
CRISPR and Fanzor in sickle cell disease: current progress and future prospects
Humoudi, A. Y. A., Alotaibi, A. G., Alosaimi, N. F., Alshalani, A., Alqahtani, S. D., Alsaab, S. M., Almutiri, B. J., & Albariqi, M. M. H. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1774014
Hellbacher, E., Knight, A., Hemmingsson, P., Juto, A., Gunnarsson, I., Bruchfeld, A. N., Weiner, M., Söderbergh, A., Ohlsson, S., Pullerits, R., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848693
Controlling Hemoglobin F Expression in Sickle Cell Disease and β-thalassemia
Popp, N. A. (2026) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2026.150993
Ngo, J. C., Xu, Y., Olah, M., & Sher, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.30.735672
Self-citationGene Therapy and CRISPR-based Intervention in Sickle Cell Anemia
Dere, V. V., Patil, S. S., Kale, A. Y., & Otari, K. V. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3515
Cao, H., Wu, Z., Ji, B., Yang, S., Gonzalez-Smith, L., Vu, A. H., & Rhie, S. K. (2026) · Genome biology · doi:10.1186/s13059-026-04178-9
Towards efficient perturbation for the noncoding genome
Zhang, H., Luo, S., Wang, X., Lin, L., Liang, R., Zhong, C., Zhang, Y., Zhao, W., Chen, Z., Liu, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76567-4 · Cited by 1
An Integrated Gene Therapy Strategy for γ-Globin Addition and HbF Reactivation in β-Thalassemia
Paschoudi, K., Vasiloudis, N.-I., Papadopoulos, F., Nikolaou, X., Παπαδοπούλου, Α., Sova, P., Yannaki, E., & Psatha, N. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030019
Targeted genomic integration and rearrangement using prime assembly
Levesque, S., Kawashima, N., Hwang, G., Zeng, J., Toskov, V., Barry, T., Mannherz, W. P., Homfeldt, L., Becerra, B., Schoonenberg, V. A. C., et al. (2026) · Nature · doi:10.1038/s41586-026-11024-2 · Cited by 3
Self-citationZhang, L., Ma, B., Zhang, Y., Wang, X., Wang, L., Wang, R., Zhang, Y., & Shang, F. (2026) · Animals · doi:10.3390/ani16182956
Human genetics implicates a BACH2–NRF2 axis in fetal haemoglobin activation
Guo, C., Arora, U. P., Cheng, X., Xu, W., Cato, L. D., Li, R., Lu, H. Y., Lee, A., Yu, F., Agarwal, G., et al. (2026) · Nature · doi:10.1038/s41586-026-11113-2 · Cited by 11
Evolution of Gene Therapy in Hematology
Loves, R. H., & Kohn, D. B. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.005
Gene Therapy for Hemoglobinopathies
Gibson, N. M., Patel, J., & Kwiatkowski, J. L. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.09.014
CRISPR-based functional screening of noncoding regulatory elements
Roh, H., & Liau, B. B. (2026) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2026.102804
Massively parallel functional genomic assays in endocrinology: from promise to delivery
Xu, J., Aslanzadeh, V., Kudla, G., & Semple, R. K. (2026) · Journal of Molecular Endocrinology · doi:10.1530/jme-25-0134
Metadata
- Authors
- Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Broad Institute (US)
- RIKEN BioResource Research Center (JP)
- University of Tsukuba (JP)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Feng
- Orkin, Stuart H.
- Bauer, Daniel E.
- ORCID
- Venue
- Nature
- Published
- 2015-09-16
- Volume
- 527
- Issue
- 7577
- Pages
- 192-197
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4644101
- OpenAlex
- W1855348513
- Cited by
- 886
- References
- 65
- Citations by year
- 2026: 43 · 2025: 72 · 2024: 76 · 2023: 79 · 2022: 68 · 2021: 91 · 2020: 85 · 2019: 92 · 2018: 87 · 2017: 94 · 2016: 89 · 2015: 8
- FWCI
- 51.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- Howard Hughes Medical Institute
- U.S. Public Health Service (R01 A1084905)
- National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, R01HL119099)
- National Institute of Mental Health (DP1MH100706, R01MH110049)
- National Human Genome Research Institute (K99HG008171, R01HG005085, K99HG008399)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, 5R01-DK097768, R01DK097768, F30DK103359, K08DK093705)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- BCL11A, enhancers, CRISPR/Cas9, fetal hemoglobin, sickle cell disease, beta-thalassemia, enhancer architecture, erythroblasts
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Carrier Proteins, Cells, Cultured, DNA-Binding Proteins, Enhancer Elements, Genetic, Erythroblasts, Fetal Hemoglobin, Genetic Engineering, Humans, Molecular Sequence Data, Nuclear Proteins, Organ Specificity, Repressor Proteins, Species Specificity, Reproducibility of Results, Mutagenesis, Genome, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
